For example, in those with a clinical diagnosis of TSC, pathogenic variants are identified using standard technology in around 85% of patients, while somatic mosaicism for pathogenic variants in TSC1 or TSC2 occurs in at least 10% of patients [283]. This evidence concerns the gene TSC2 and tuberous sclerosis.